Adalta Ltd Cash Flow Conversion Efficiency

Latest as of December 2025: 2.240x

Adalta Ltd cash flow conversion efficiency. Based on the latest financial reports, Adalta Ltd (1AD) has a cash flow conversion efficiency ratio of 2.240x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-489.87K ≈ $-346.61K USD) by net assets (AU$-218.66K ≈ $-154.71K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Adalta Ltd (2013–2025)

Cash flow conversion efficiency of Adalta Ltd from 2013 to 2025. This chart illustrates how Adalta Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Adalta Ltd (1AD) stock price for real-time trading data and today's change.

Adalta Ltd Cash Flow Conversion Ratio Explained

Adalta Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Adalta Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Adalta Ltd ranked by their cash flow conversion efficiency. Also see 1AD stock market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Intelicanna Ltd
TA:INTL
-0.023x
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
-0.167x
Nandani Creation Limited
NSE:JAIPURKURT
-0.166x
Gaxos.ai Inc
NASDAQ:GXAI
-0.067x
TruCap Finance Limited
NSE:TRU
1.175x
Bulletin Resources Ltd
AU:BNR
-0.046x
Balkrishna Paper Mills Limited
NSE:BALKRISHNA
0.020x
Ambertech Ltd
AU:AMO
-0.183x

Annual Cash Flow Conversion Efficiency for Adalta Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Adalta Ltd from 2013 to 2025. Review cash generation quality of Adalta Ltd to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$-598.24K
≈ $-423.30K
AU$-2.94 Million
≈ $-2.08 Million
4.909x +289.49%
2024-06-30 AU$2.03 Million
≈ $1.44 Million
AU$-5.26 Million
≈ $-3.72 Million
-2.590x +3.59%
2023-06-30 AU$1.91 Million
≈ $1.35 Million
AU$-5.13 Million
≈ $-3.63 Million
-2.687x -253.48%
2022-06-30 AU$5.38 Million
≈ $3.81 Million
AU$-4.09 Million
≈ $-2.89 Million
-0.760x -1.52%
2021-06-30 AU$6.39 Million
≈ $4.52 Million
AU$-4.78 Million
≈ $-3.38 Million
-0.749x +52.93%
2020-06-30 AU$3.70 Million
≈ $2.62 Million
AU$-5.89 Million
≈ $-4.17 Million
-1.591x -104.89%
2019-06-30 AU$7.49 Million
≈ $5.30 Million
AU$-5.82 Million
≈ $-4.12 Million
-0.776x +19.51%
2018-06-30 AU$4.07 Million
≈ $2.88 Million
AU$-3.93 Million
≈ $-2.78 Million
-0.965x -100.48%
2017-06-30 AU$7.75 Million
≈ $5.48 Million
AU$-3.73 Million
≈ $-2.64 Million
-0.481x -334.96%
2016-06-30 AU$10.62 Million
≈ $7.51 Million
AU$-1.17 Million
≈ $-830.93K
-0.111x +94.35%
2015-06-30 AU$705.89K
≈ $499.46K
AU$-1.38 Million
≈ $-978.16K
-1.958x +73.76%
2014-06-30 AU$172.82K
≈ $122.28K
AU$-1.29 Million
≈ $-912.79K
-7.465x -219.41%
2013-06-30 AU$283.92K
≈ $200.89K
AU$-663.54K
≈ $-469.50K
-2.337x --

About Adalta Ltd

AU:1AD Australia Biotechnology
Market Cap
$5.41 Million
AU$7.65 Million AUD
Market Cap Rank
#28328 Global
#1456 in Australia
Share Price
AU$0.00
Change (1 day)
+50.00%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$0.37
About

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more